Traducción en proceso. Mostrando versión en inglés.

Acarix Q4 2025 presentation: Revenue up 26% as CADScor adoption accelerates

ArchivadoVerificado|4 artículos|2 fuentes|1 bloques

Detectado: Actualizado: Analizado:

Salud Tecnología

Hechos Reportados

Datos observables compartidos por todas las narrativas

•Acarix reported a 26% increase in revenue for Q4 2025.
•The revenue growth was attributed to accelerated adoption of the CADScor diagnostic technology.
•Acarix presented these results during its Q4 2025 earnings call and presentation.

Qué Podría Pasar Si...

▸If CADScor adoption continues to accelerate Acarix could sustain or increase its revenue growth, impacting its market position in cardiovascular diagnostics.

Inicia sesión para ver todos los escenarios y señales.

Actores Clave

Organizaciones

🏛Acarix

Cobertura por Fuentes

FINANCE

4 artículos

Más cobertura relacionada

Más sobre Acarix

Señales

Single-block coverageLow source diversity

Eventos Relacionados

▸Axsome Reports 57% Q1 Revenue Growth, Eyes $18B Peak SalesArchivado ▸RxSight projects $120M–$135M revenue for 2026 with commercial pushArchivado ▸Arcutis Q4 2025 Revenue Beats Led by ZORYVE ProfitabilityArchivado ▸Corcept projects $900M–$1B revenue as relacorilant oncology approval nearsArchivado ▸Bio-Rad outlines 2026 margin expansion and 0.5%-1.5% revenue growth guidance amid operational improvements

Fuentes (4)

FINANCESeeking Alpha - Market NewsAvita Medical outlines 2026 revenue target of $80M-$85M as reimbursement clarity supports multiproduct utilization FINANCESeeking Alpha - Market NewsKaryopharm signals $130M–$150M revenue target for 2026 with pivotal myelofibrosis data readout ahead FINANCEInvesting.com - NewsAcarix Q4 2025 presentation: Revenue up 26% as CADScor adoption accelerates

Acarix reported a 26% increase in revenue for the fourth quarter of 2025, driven by accelerated adoption of its CADScor technology. The company highlighted this growth during its Q4 2025 presentation and earnings call, emphasizing expanding market penetration. This revenue increase reflects growing demand for CADScor, a diagnostic tool for coronary artery disease, positioning Acarix for continued growth. The financial performance contrasts with other healthcare companies like Avita Medical and Karyopharm, which have also set ambitious revenue targets for 2026 based on product utilization and clinical data milestones.